

Zoom In on **Dementia & Alzheimer's**

Dementia Drugs Town Hall:

What's New, What's Old, What's Approved,
What's Covered

Ask questions live!



Cynthia Lemere, PhD

Scientist at Brigham and Women's Hospital and
Associate Professor of Neurology Harvard Medical School



Supported in part by educational grants from Lilly and Genentech



Alzheimer's
Disease
Research



Housekeeping

- This program is being recorded and live streamed.
- Please ask questions! Use the 'raise hand' feature, or type questions into the chat box.
- You will be unmuted to ask your question live.
- Personal questions cannot be addressed.

Zoom In on Dementia & Alzheimer's

Donanemab: slowed clinical decline by **35%** and showed **40%** slowing of decline in a measure of the ability to perform activities of daily living

Leqembi: slowed clinical decline by **27%** and showed **37%** slowing of decline in a measure of the ability to perform activities of daily living

WHAT IS THE DIFFERENCE?



Questions?

If your question was not answered today or if you have suggestions for future topics email

reply@brightfocus.org

Free Publications About Alzheimer's Disease

- Understanding Alzheimer's Disease: It's Not Just Forgetfulness
- Clinical Trials: Your Questions Answered
- Staying Safe: Wandering and the Alzheimer's Patient
- Managing Stress: Care for the Caregiver
- Alzheimer's Diagnosis: Questions to Ask Your Doctor

To request free copies of these and other brochures,

call 855-345-6237 or email info@brightfocus.org



Resources

LEQEMBI®: FDA-Approved www.LEQEMBI.com

Eisai Patient Support Program: www.eisaipatientsupport/leqembi or call 1-833-453-7362.

DONANEMAB: Not Yet FDA-Approved <https://investor.lilly.com/news-releases/news-release-details/lillys-donanemab-significantly-slowed-cognitive-and-functional>

Lilly continues to study Donanemab, which is given by infusion, in multiple clinical trials including:

TRAILBLAZER-ALZ 3, focused on preventing symptomatic Alzheimer's disease (AD) in participants with preclinical (non-symptomatic) AD;

TRAILBLAZER-ALZ 6, focused on expanding our understanding of ARIA through novel MRI sequences, blood-based biomarkers and different dosing regimens of Donanemab.

REMTERNETUG: Not Yet FDA-Approved <https://trials.lilly.com/en-US/trial/351135>

Lilly is studying Remternetug, which is given by injection under the skin, in participants with early symptomatic AD:

TRAILRUNNER-ALZ 1, focused on targeting toxic amyloid plaques linked to AD

ADUHELM®: FDA-Approved <https://www.aduhelm.com>

Biogen Support Services for Patients: Call 1-833-425-9360 Monday–Friday.



Join Us for Our Next Episode

Thursday, September 21 at 1 pm ET/10 am PT

Zoom in on **Dementia & Alzheimer's**

A free virtual discussion
with medical experts.

